Gilead Sciences Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
Le Lézard2h
Logitech Announces Fourth Consecutive Quarter of Sales Growth
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR ? Logitech International (SIX: LOGN) today announced financial results for the third quarter of Fiscal Year 2025. Sales were $1.34 billion ...
Business Wire3h
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Crohn’s Disease Pipeline Insights, FDA Approvals, Drugs, Companies Report | DelveInsight
The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid competition
Legend Biotech Corporation (NASDAQ:LEGN), with a market capitalization of $6.74 billion, has emerged as a prominent player in the biotechnology sector, primarily due to the success of its flagship ...